Ibogaine: therapeutic potential, cardiac safety, and translational perspectives
Safety-focused review emphasizing need for rigorous clinical pathways.
Evidence memo
Also tracked as: Iboga alkaloid
An addiction-treatment research compound with high public interest and unusually important cardiac safety concerns.
Safety/regulatory watch. Evidence level: Safety/regulatory watch.
Whether potential addiction-treatment signals can be studied in a standardized way that addresses cardiac and neurologic safety risks.
Ibogaine is discussed for opioid and substance-use disorders, often by people seeking options after failed standard approaches.
There are observational and translational signals, but safety literature includes serious cardiac-risk concerns.
Whether a regulated clinical pathway can separate any therapeutic signal from unacceptable acute risk.
This is a safety/regulatory watch item. The Watchlist does not provide clinic, sourcing, or use guidance.
Controlled trials, cardiac monitoring standards, analog development, and regulatory decisions.
The safety boundary is not a footnote; it is the center of the evidence map.
Safety-focused review emphasizing need for rigorous clinical pathways.
Safety case report relevant to cardiac risk boundary.